目的观察酒石酸长春瑞滨脂质体注射液的体内抗肿瘤作用。方法建立小鼠肝癌H22肿瘤模型和人大细胞肺癌NCI-H460移植肿瘤模型,探讨长春瑞滨脂质体的抗肿瘤作用。结果长春瑞滨脂质体单次以20、10、5和2.5 mg·kg-1静脉注射,对小鼠H22实体瘤的抑瘤率分别是82.1%、75.8%、63.2%和35.4%,酒石酸长春瑞滨注射液(20和10 mg·kg-1)的抑瘤率分别是45.8%和37.1%。长春瑞滨脂质体8 mg·kg-1间隔3 d静脉给药3次,可以显著抑制NCI-H460肿瘤的生长。长春瑞滨脂质体对H22肿瘤和NCI-H460的抑制作用明显优于长春瑞滨游离药,且与给药剂量正相关。结论相同给药剂量下,长春瑞滨脂质体的体内抗肿瘤作用显著优于长春瑞滨注射液。 Objective To observe the antitumor effect of vinorelbine tartrate liposome injection in vivo. Methods Mouse hepatocellular carcinoma H22 tumor model and human large cell lung cancer NCI-H460 transplanted tumor model were established to investigate the antitumor effect of vinorelbine liposomes. Results The inhibition rate of vinorelbine liposomes to mice with H22 solid tumors was 82.1%, 75.8%, 63.2% and 35.4% respectively by single intravenous injection of 20, 10, 5 and 2.5 mg · kg-1. The inhibition rates of vinorelbine injection (20 and 10 mg · kg-1) were 45.8% and 37.1%, respectively. Vinorelbine liposome 8 mg · kg-1 3 d intravenously three times, can significantly inhibit the growth of NCI-H460 tumor. The inhibitory effect of vinorelbine liposomes on H22 tumor and NCI-H460 was significantly better than that of vinorelbine free drug, and was positively correlated with the dose of vinorelbine. Conclusion The antitumor effect of vinorelbine liposomes in vivo was significantly better than vinorelbine injection at the same dosage.